Skip to main content
SpringerLink
Log in

SGLT-2-Hemmer bei Diabetes und Nephropathie

Diese Therapie wirkt auch renoprotektiv

SGLT-2-Inhibitors and kidney function

  • FORTBILDUNG . SEMINAR
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Für Diabetiker mit Nephropathie gibt es eine neue Therapieoption: die SGLT-2-Hemmer. Wie sie wirken und auf was Sie bei der Behandlung achten müssen, erfahren Sie im nachfolgenden Beitrag.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Deutscher Gesundheitsbericht Diabetes 2018 (https://www.diabetesde.org/system/files/documents/gesundheitsbericht_2018.pdf)

  2. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. In: Kidney Disease: Improving Global Outcomes [KDIGO] CKD Work Group (Hrsg.): Kidney Int. Suppl. 3, Nr. 1, 2013, S. 1–150 (KDIGO CKD 2012 [PDF]).

  3. Bakris et al. Treatment of diabetic kidney disease. https://www.uptodate.com/contents/treatment-of-diabetic-kidney-disease

  4. Umanath et al. Update on Diabetic Nephropathy: CoreCurriculum 2018. Am J Kidney Dis. 71(6):884–895. Published onlineFebruary 2, 2018

    Article  Google Scholar 

  5. Mosenzon et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019 Aug;7(8):606–617.

    Article  CAS  Google Scholar 

  6. Wanner et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117–28.

    Article  Google Scholar 

  7. Perkovic et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295–2306.

    Article  CAS  Google Scholar 

  8. Thomas et al. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018 Oct;61(10):2098–2107

    Article  CAS  Google Scholar 

  9. Zelniker TA et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;339:31–39

    Article  Google Scholar 

  10. https://clinicaltrials.gov/Empagliflozin bzw. https://clinicaltrials.gov/dapagliflozin

  11. Peters AL. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015 Sep;38(9):1687–93.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabeteszentrum Bogenhausen, Cosimastraße 2, D-81927, München, Deutschland

    Marcel Roos

Authors
  1. Marcel Roos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcel Roos.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roos, M. Diese Therapie wirkt auch renoprotektiv. MMW - Fortschritte der Medizin 161 (Suppl 3), 69–73 (2019). https://doi.org/10.1007/s15006-019-1090-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-019-1090-7

Keywords

Search

Navigation